4.57
price down icon11.09%   -0.57
after-market Handel nachbörslich: 4.63 0.06 +1.31%
loading
Schlusskurs vom Vortag:
$5.14
Offen:
$5.14
24-Stunden-Volumen:
188.44K
Relative Volume:
0.80
Marktkapitalisierung:
$42.78M
Einnahmen:
$24.99M
Nettoeinkommen (Verlust:
$-108.83M
KGV:
-0.3041
EPS:
-15.0286
Netto-Cashflow:
$-91.62M
1W Leistung:
-18.54%
1M Leistung:
-49.50%
6M Leistung:
-43.23%
1J Leistung:
-72.54%
1-Tages-Spanne:
Value
$4.57
$5.14
1-Wochen-Bereich:
Value
$4.57
$5.84
52-Wochen-Spanne:
Value
$4.57
$17.04

Adicet Bio Inc Stock (ACET) Company Profile

Name
Firmenname
Adicet Bio Inc
Name
Telefon
617-482-2333
Name
Adresse
131 DARTMOUTH STREET, BOSTON
Name
Mitarbeiter
102
Name
Twitter
Name
Nächster Verdiensttermin
2026-11-04
Name
Neueste SEC-Einreichungen
Name
ACET's Discussions on Twitter

Compare ACET vs VRTX, MRNA, REGN, ARGX, ONC

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
ACET icon
ACET
Adicet Bio Inc
4.57 42.78M 24.99M -108.83M -91.62M -15.03
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
499.74 126.66B 12.34B 4.34B 3.71B 16.87
MRNA icon
MRNA
Moderna Inc
218.01 87.04B 2.23B -3.19B -1.60B -8.1462
REGN icon
REGN
Regeneron Pharmaceuticals Inc
790.74 81.41B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
819.14 51.51B 4.16B 1.29B 734.26M 19.58
ONC icon
ONC
Beone Medicines Ltd Adr
369.06 41.75B 5.76B 514.49M 1.10B 4.4813

Adicet Bio Inc Stock (ACET) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2026-05-05 Fortgesetzt Jefferies Buy
2024-09-30 Fortgesetzt Guggenheim Buy
2024-09-11 Herabstufung H.C. Wainwright Buy → Neutral
2023-06-27 Herabstufung Guggenheim Buy → Neutral
2023-06-27 Herabstufung JMP Securities Mkt Outperform → Mkt Perform
2023-06-01 Herabstufung JP Morgan Overweight → Neutral
2022-09-21 Eingeleitet JP Morgan Overweight
2022-03-31 Eingeleitet SMBC Nikko Outperform
2022-03-08 Eingeleitet Truist Buy
2022-03-04 Eingeleitet Jefferies Buy
2021-05-18 Eingeleitet BTIG Research Buy
2021-04-23 Eingeleitet H.C. Wainwright Buy
2021-04-14 Eingeleitet Canaccord Genuity Buy
2021-04-08 Eingeleitet Guggenheim Buy
2020-11-04 Eingeleitet B. Riley Securities Buy
2020-10-27 Eingeleitet JMP Securities Mkt Outperform
2020-10-16 Eingeleitet Wedbush Outperform
Alle ansehen

Adicet Bio Inc Aktie (ACET) Neueste Nachrichten

pulisher
Sep 30, 2026

A new hire waits a year to gain the right to buy Adicet shares - Stock Titan

Sep 30, 2026
pulisher
Sep 28, 2026

Every patient in Adicet's lupus study stopped immune-suppressing drugs - Stock Titan

Sep 28, 2026
pulisher
Sep 28, 2026

Adicet Bio (Nasdaq:ACET)Stock Analysis - Simply Wall Street

Sep 28, 2026
pulisher
Sep 28, 2026

Adicet Bio (NasdaqCM:ACET) Stock Forecast & Analyst Predictions - Simply Wall Street

Sep 28, 2026
pulisher
Sep 25, 2026

At $10.99 a share, Gossamer Bio (GOSS) director Sandra Milligan receives a stock option. - Stock Titan

Sep 25, 2026
pulisher
Sep 25, 2026

Gossamer Bio grants director options on 10,000 shares - Stock Titan

Sep 25, 2026
pulisher
Sep 25, 2026

Devpratim Chakraborty, Brigit SVP, reported no direct Upbound Group (UPBD) shares as of September 22. - Stock Titan

Sep 25, 2026
pulisher
Sep 18, 2026

[Form 3] Electra Therapeutics, Inc. Initial Statement of Beneficial Ownership - Stock Titan

Sep 18, 2026
pulisher
Sep 18, 2026

Red Robin Gourmet Burgers, Inc.Common Stock (NQ: RRGB - The Chronicle-Journal

Sep 18, 2026
pulisher
Sep 18, 2026

Adicet Bio, Inc. (NASDAQ:ACET) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat

Sep 18, 2026
pulisher
Sep 11, 2026

Adicet Bio (NASDAQ:ACET) Stock Passes Above Two Hundred Day Moving AverageTime to Sell? - marketbeat.com

Sep 11, 2026
pulisher
Sep 10, 2026

Stock option sale planned at ScanSource (NASDAQ: SCSC) for 2026 - Stock Titan

Sep 10, 2026
pulisher
Sep 08, 2026

Adicet Bio Highlights Prula-cel Autoimmune CAR-T Pipeline Progress - TipRanks

Sep 08, 2026
pulisher
Sep 08, 2026

Adicet Bio posts September 2026 investor presentation outlining prula-cel and ADI-212 clinical timelines - TradingView

Sep 08, 2026
pulisher
Sep 05, 2026

Adicet Bio Stock Price Forecast. Should You Buy ACET? - StockInvest.us

Sep 05, 2026
pulisher
Sep 03, 2026

Wall Street Analysts See a 258.21% Upside in Adicet Bio (ACET): Can the Stock Really Move This High? - Yahoo Finance

Sep 03, 2026
pulisher
Sep 03, 2026

Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year? - Yahoo Finance

Sep 03, 2026
pulisher
Sep 03, 2026

Adicet Bio (NASDAQ:ACET) Upgraded to Strong-Buy at Jefferies Financial Group - marketbeat.com

Sep 03, 2026
pulisher
Sep 03, 2026

[425] Passage BIO, Inc. Business Combination Communication | PASG SEC FilingForm 425 - Stock Titan

Sep 03, 2026
pulisher
Sep 02, 2026

A biotech CEO will speak in New York Sept. 15. Audio will be online. - Stock Titan

Sep 02, 2026
pulisher
Sep 01, 2026

Adicet Bio (NASDAQ: ACET) Advances ADI-212 Clinical Trial for mCRPC and Prepares Prula-Cel Data Release - Kalkine Media

Sep 01, 2026
pulisher
Sep 01, 2026

Adicet Bio (NASDAQ: ACET) Advances ADI-212 Clinical Trial for mCRPC, Prula-cel Data Expected in September 2026 - Kalkine Media

Sep 01, 2026
pulisher
Sep 01, 2026

Adicet Bio, Inc. (NASDAQ:ACET) Sees Large Drop in Short Interest - MarketBeat

Sep 01, 2026
pulisher
Sep 01, 2026

Adicet Bio advances CAR-T programs and clinical pipeline - grafa.com

Sep 01, 2026
pulisher
Sep 01, 2026

Adicet Bio completes prula-cel Phase 1 SLE analysis - TipRanks

Sep 01, 2026
pulisher
Sep 01, 2026

Adicet Bio says prula-cel last patient visit complete; topline data due Sept 2026, ADI-212 IND cleared - TradingView

Sep 01, 2026
pulisher
Sep 01, 2026

The final patient visit is complete in a lupus cell-therapy study. Adicet Bio expects results from 22 patients in September. - stocktitan.net

Sep 01, 2026
pulisher
Aug 31, 2026

Adicet Bio grants a new hire options on 1,500 shares over four years - Stock Titan

Aug 31, 2026
pulisher
Aug 31, 2026

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Aug 31, 2026
pulisher
Aug 29, 2026

Adicet Bio (NASDAQ:ACET) Stock Rating Lowered by Wall Street Zen - marketbeat.com

Aug 29, 2026
pulisher
Aug 28, 2026

Press Release Service: Adicet Bio Announces FDA Clearance of IND Application for ADI-212 - CRISPR Medicine News

Aug 28, 2026
pulisher
Aug 27, 2026

Adicet Bio Gets FDA Clearance for IND for ADI-212 in prostate cancer - marketscreener.com

Aug 27, 2026
pulisher
Aug 27, 2026

Adicet Bio receives FDA clearance for prostate cancer trial By Investing.com - Investing.com Canada

Aug 27, 2026
pulisher
Aug 27, 2026

Adicet Bio receives FDA clearance for prostate cancer trial By Investing.com - Investing.com India

Aug 27, 2026
pulisher
Aug 27, 2026

Adicet Bio receives FDA clearance for prostate cancer trial By Investing.com - Investing.com UK

Aug 27, 2026
pulisher
Aug 27, 2026

Adicet Bio receives FDA clearance for prostate cancer trial - investing.com

Aug 27, 2026
pulisher
Aug 27, 2026

FDA clears Adicet Bio's application to study a gene-edited prostate cancer therapy - Stock Titan

Aug 27, 2026
pulisher
Aug 24, 2026

Here's Why You Should Add ACET Stock to Your Portfolio Now - Yahoo Finance

Aug 24, 2026
pulisher
Aug 21, 2026

Adicet (ACET) Trading: Adds 0.32% to Close at $9.41 in the Current Update; Key Range - vinanet.vn

Aug 21, 2026
pulisher
Aug 19, 2026

ETFs Investing in Adicet Bio Inc Stocks - TradingView

Aug 19, 2026
pulisher
Aug 18, 2026

Are Medical Stocks Lagging Adicet Bio (ACET) This Year? - Eastern Progress

Aug 18, 2026
pulisher
Aug 18, 2026

Are Medical Stocks Lagging Adicet Bio (ACET) This Year? - Yahoo Finance

Aug 18, 2026
pulisher
Aug 16, 2026

ACET Q2 2026 Earnings: Narrower-Than-Expected Loss of $1.99 Per Share Buoys SharesSegment Revenue Breakdown - vinanet.vn

Aug 16, 2026
pulisher
Aug 14, 2026

RA Capital discloses 9.99% Adicet Bio (ACET) stake with warrant blocker - Stock Titan

Aug 14, 2026
pulisher
Aug 14, 2026

Adicet Bio (ACET) - Zacks Investment Research

Aug 14, 2026
pulisher
Aug 14, 2026

Adicet Bio: A Cheap Gamma Delta T-Cell Play (NASDAQ:ACET) - Seeking Alpha

Aug 14, 2026
pulisher
Aug 14, 2026

Wall Street Analysts Think Adicet Bio (ACET) Could Surge 301.57%: Read This Before Placing a Bet - Zacks Investment Research

Aug 14, 2026
pulisher
Aug 14, 2026

Wall Street Analysts Think Adicet Bio (ACET) Could Surge 301.57%: Read This Before Placing a Bet - Yahoo Finance

Aug 14, 2026
pulisher
Aug 12, 2026

Adicet Bio (ACET) Edges Higher to $8.26 as Biotech Stock Consolidates Between Key LevelsETF Flow - Vinanet

Aug 12, 2026
pulisher
Aug 12, 2026

Adicet Bio (ACET) Edges Higher to $8.26 as Biotech Stock Consolidates Between Key LevelsVanna Flow - dars.gov.et

Aug 12, 2026

Finanzdaten der Adicet Bio Inc-Aktie (ACET)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Adicet Bio Inc-Aktie (ACET) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
OrbiMed Genesis Master Fund, L
Shareholder
Apr 09 '26
Proposed Sale
6.55
78,499
514,168
0
OrbiMed Israel Partners II, L.
Shareholder
Apr 08 '26
Proposed Sale
6.55
40,416
264,725
0
ORBIMED ADVISORS LLC
10% Owner
Apr 08 '26
Sale
6.42
72,939
468,082
0
OrbiMed Israel Partners Limite
Shareholder
Apr 07 '26
Proposed Sale
6.43
64,242
413,076
0
ORBIMED ADVISORS LLC
10% Owner
Apr 07 '26
Sale
6.52
31,719
206,765
32,523
RA CAPITAL MANAGEMENT, L.P.
10% Owner
Feb 19 '26
Buy
7.21
74,268
535,472
1,107,873
RA CAPITAL MANAGEMENT, L.P.
10% Owner
Feb 18 '26
Buy
7.04
74,577
525,022
1,033,605
ORBIMED ADVISORS LLC
10% Owner
Oct 08 '25
Buy
1.00
5,000,000
5,000,000
9,026,359
$6.58
price down icon 4.22%
$9.94
price down icon 3.21%
$5.53
price down icon 3.66%
$11.27
price down icon 6.16%
$18.60
price down icon 1.74%
WVE WVE
$3.13
price down icon 1.88%
Kapitalisierung:     |  Volumen (24h):